Black Diamond Therapeutics (BDTX) Assets Average (2020 - 2026)
Black Diamond Therapeutics' (BDTX) quarterly Assets Average came in at $138.0 million in Q1 2026, down 7.68% YoY from $149.4 million in Q1 2025, and down 8.25% on a QoQ basis from $150.4 million in Q4 2025.
Black Diamond Therapeutics (BDTX) Assets Average (2020 - 2026) Analysis & Trends
Black Diamond Therapeutics (BDTX) has 7 years of Assets Average data on file, last reported at $138.0 million in Q1 2026.
- Quarterly Assets Average fell 7.68% year-over-year to $138.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $138.0 million (down 7.68% YoY) and the FY2025 annual result came in at $132.8 million, down 5.53% from the prior year.
- Assets Average slipped to $138.0 million in Q1 2026, from $150.4 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $233.6 million in Q1 2022 to a low of $127.7 million in Q2 2023.
- A 5-year average of $160.5 million and a median of $150.4 million in 2025 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2023 — Assets Average sank 38.93% — and 2025, when it increased 17.14%.
- Tracing BDTX's Assets Average over 5 years: stood at $168.3 million in 2022, then retreated by 1.7% to $165.5 million in 2023, then decreased by 21.28% to $130.3 million in 2024, then grew by 15.43% to $150.4 million in 2025, then declined by 8.25% to $138.0 million in 2026.
- The last three Assets Average figures came in at $138.0 million (Q1 2026), $150.4 million (Q4 2025), and $162.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 5.34 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 25.27 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 2.09 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.82 Bn |
| 10 | Black Diamond Therapeutics | 125.92 Mn | 15.42 Mn | - | 128.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 128.98 Mn |
| Mar 31, 2026 | 137.97 Mn |
| Dec 31, 2025 | 150.37 Mn |
| Sep 30, 2025 | 162.06 Mn |
| Jun 30, 2025 | 171.32 Mn |
| Mar 31, 2025 | 149.44 Mn |
| Dec 31, 2024 | 130.27 Mn |
| Sep 30, 2024 | 143.94 Mn |
| Jun 30, 2024 | 146.25 Mn |
| Mar 31, 2024 | 150.54 Mn |
| Dec 31, 2023 | 165.47 Mn |
| Sep 30, 2023 | 146.13 Mn |
| Jun 30, 2023 | 127.73 Mn |
| Mar 31, 2023 | 145.92 Mn |
| Dec 31, 2022 | 168.34 Mn |
| Sep 30, 2022 | 189.63 Mn |
| Jun 30, 2022 | 209.16 Mn |
| Mar 31, 2022 | 233.58 Mn |
| Dec 31, 2021 | 260.90 Mn |
| Sep 30, 2021 | 281.00 Mn |